FDA's Oncologic Drugs Advisory Committee has voted 12 to 2 in favor of imetelstat for patients with LR-MDS. Read why Geron ...
Geron Corporation (GERN) reported Loss for its first quarter that increased from the same period last year but beat the Street ...
Geron Corp. (GERN) on ...
Geron (GERN) delivered earnings and revenue surprises of 10% and 102.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
TD Cowen has started coverage of Geron (NASDAQ:GERN) with a buy rating, citing the market potential of its oncology drug ...
Geron presents their latest quarterly figures.Analysts expect Geron will report losses per share of $0.096.Go here to watch Geron stock ...
Fintel reports that on April 29, 2024, TD Cowen initiated coverage of Geron (NasdaqGS:GERN) with a Buy recommendation.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financi ...
The Montana State men’s basketball team had another entrant into the transfer portal on Wednesday. Jaden Geron, a 6-foot-8 ...
Fintel reports that on April 30, 2024, Baird downgraded their outlook for Geron (NasdaqGS:GERN) from Outperform to Neutral. ...
Montana State University men's basketball saw both the benefits and downside of the transfer portal Wednesday as the Bobcats ...
Geron (NASDAQ:GERN) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...